Manganese-induced parkinsonism associated with methcathinone (Ephedrone) abuse

Archives of Neurology

Volumn 64, Issue 6, 2007, Pages 886-889

  De Bie, Rob M A ^a,c   Gladstone, Richard M ^e   Strafella, Antonio P ^a,b   Ko, Ji Hyun ^d   Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MCGILL UNIVERSITY   (Canada)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; EDETATE CALCIUM DISODIUM; LEVODOPA; MANGANESE; METHCATHINONE; PERMANGANATE POTASSIUM; PRAMIPEXOLE; PSEUDOEPHEDRINE; SELEGILINE;

ADULT; ARTICLE; CASE REPORT; DRUG ABUSE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LABORATORY TEST; MALE; NEUROLOGIC EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SELF INJECTION; SOMNOLENCE;

ADULT; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE POISONING; PARKINSONIAN DISORDERS; PROPIOPHENONES; SUBSTANCE-RELATED DISORDERS;

EID: 34250308005     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.6.886     Document Type: Article

References (18)

1. Cersosimo MG, Koller WC. The diagnosis of manganese-induced parkinsonism. Neurotoxicology. 2006;27:340-346.
2. Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord. 1995;10:714-722.
3. Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology. 1991;181:117-120.
4. Levin OS. "Ephedron" encephalopathy [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105:12-20.
5. Aquilonius S, Sikk K, Taba P, et al. The Sudafed story: manganism, ephedrone or both [abstract]? Mov Disord. 2006;21(suppl 15):S373.
6. What is methcathinone? http://designer-drugs.com/pte/12.162.180.114/dcd /chemistry/methcatfaq.22.html. Accessed March 21, 2007.
7. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699.
8. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128:1498-1510.
9. Wooten GF, Lopes MB, Harris WO, Reagan TJ, Vandenberg SR. Pallidoluysian atrophy: dystonia and basal ganglia functional anatomy. Neurology. 1993;43:1764-1768.
10. Huang CC, Chu NS, Lu CS, Chen RS, Calne DB. Long-term progression in chronic manganism: ten years of follow-up. Neurology. 1998;50:698-700.
11. Schaumburg HH, Herskovitz S, Cassano VA. Occupational manganese neurotoxicity provoked by hepatitis C [published correction appears in Neurology. 2006;67:1902]. Neurology. 2006;67:322-323.
12. Huang CC, Weng YH, Lu CS, Chu NS, Yen TC. Dopamine transporter binding in chronic manganese intoxication. J Neurol. 2003;250:1335-1339.
13. Wolters EC, Huang CC, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol. 1989;26:647-651.
14. Shinotoh H, Snow BJ, Hewitt KA, et al. MRI and PET studies of manganese-intoxicated monkeys. Neurology. 1995;45:1199-1204.
15. Racette BA, Antenor JA, McGee-Minnich L, et al. [18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord. 2005;20:492-496.
16. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci. 1996;23:95-98.
17. Maeda H, Sato M, Yoshikawa A, et al. Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology. 1997;39:546-550.
18. Park NH, Park JK, Choi Y, et al. Whole blood manganese correlates with high signal intensities on T1-weighted MRI in patients with liver cirrhosis. Neurotoxicology. 2003;24:909-915.